Association between NAFLD and risk of prevalent chronic kidney disease: Why there is a difference between East and West?

Min Zhang
  Huashan Hospital Fudan University

Su Lin
  Fujian medical university

Mingfang Wang
  Mindong Hospital of Ningde City

Jiaofeng Huang
  Fujian medical university

Shiying Liu
  Fujian medical university

Sumei Wu
  Fujian Medical university

Haoyang Zhang
  Sun Yat-Sen University

Zimu Wu
  Fujian medical university

Wenyue Liu
  Wenzhou Medical University

Dongchu Zhang
  Wenzhou Medical University

Chuanming Hao
  Huashan Hospital Fudan University

Yueyong Zhu
  First Affiliated Hospital of Fujian Medical University

Minghua Zheng
  Wenzhou Medical University

Xiaozhong Wang

Research article

Keywords: non-alcoholic fatty liver disease, chronic renal disease

---

Abstract

Background: There is a discrepancy between west and east on the relationship between non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD). This study aimed to find out the possible reason for this and to clarify the association between NAFLD and CKD by analyzing two population-based datasets from the US and China.

Methods: Two health examination datasets from China and the US were used. CKD was defined as an estimated glomerular filtration rate (eGFR) < 60ml/min/1.73m 2 or and/or abnormal albuminuria and/or overt proteinuria. Binary logistic regression was used to examine the association between NAFLD and CKD.

Results: A total of 60965 participants were analyzed, including 11844 from the US and 51229 from China. The prevalence of NAFLD was 27.12% in the Chinese population and 36.08% in the US population (p<0.001). The proportions of CKD and late stage CKD (stages 3-5) were higher in the US population than the Chinese one. NAFLD was independently associated with an increased risk of CKD in Chinese population, whereas in the US population, the NAFLD was not an independent risk factor of CKD. In subgroup analyses which excluded late stages CKD (stages 3-5), the risks of mild renal function decline became consistent: NAFLD was associated with early stages of CKD but not the late stages of CKD in both populations.

Conclusion: NAFLD increased the risk of early stages of CKD in both Chinese and the US population. The conflicting results reported by previous studies might result from the different proportion of late stages of CKD.

Introduction

Non-alcoholic fatty liver disease (NAFLD) is characterized by lipid accumulation in the liver with the absence of significant alcohol intake or other medical conditions that cause fatty liver. It is one of the most common forms of liver diseases with a global prevalence up to 30% in general population[1]. NAFLD is also a multisystem disease, affecting extra-hepatic organs such as kidneys[2].

The relationship between NAFLD and chronic kidney disease (CKD) has attracted much attention recently. NAFLD and CKD may share common pathogenic mechanisms and thus may potentially share common therapeutic targets[3]. Growing evidence suggests that patients with NAFLD have a higher risk of CKD than non-NAFLD population[4-6]. NAFLD was responsible for a higher rate of simultaneous liver and kidney transplantation than other liver diseases[7]. Patients with NAFLD who receive a liver transplant alone may have a worse renal function after transplantation[8]. These studies highlight the significance of NAFLD as a risk for CKD. However, studies from different regions have drawn controversial conclusions on the relationship between NAFLD and CKD. For example, evidence from US population showed no associated between NAFLD and CKD after adjustment for components of the metabolic syndrome[9], while a study from Asia reported a strong independent relationship between ultrasonography-diagnosed NAFLD and CKD[10]. A latest meta-analysis also confirmed the ethnic difference between Asian and European population: the association between NAFLD and the risk of CKD is stronger in Asian population while insignificant in European population[6]. The possible reason for these contradictory conclusions might due to the heterogeneity of the study population and the different variables being adjusted in each study, yet this hypothesis has not been clearly elucidated.

In this study, we aimed to analyze the association between NAFLD and CKD in two nationally representative datasets from the US and China and try to elucidate the risk of CKD in NAFLD population from different countries.

Methods

Participants

This was a cross-sectional study. Two health examination datasets were analyzed in this study. The US dataset was retrieved from the Third American National Health and Nutrition Examination Survey (NHANES III), a nationally representative, cross-sectional study conducted by the National Center for Health Statistics of the United States from 1984 to 1994. The dataset of this study and further information are available at https://www.cdc.gov/nchs/nhanes/about_nhanes.htm. The Chinese health examination dataset was retrieved from Wenzhou Medical Center of Wenzhou People's Hospital, China, from January 2010 to December 2010.

Exclusion criteria included the presence of any of the following: without ultrasonography results, with missing data, with hepatitis B or C, and participants with excessive alcohol intake. In Chinese datasets, it was defined as >140g/week for men and>70g/week for women[11]. In US datasets, it was defined as two drinks a day. A drink means a 12-oz beer, a 4-oz glass of wine or an ounce of liquor, approximately 35g alcohol.

According to the presence of fatty liver in ultrasonography, participants were divided into the NAFLD group and non-NAFLD group.

Anthropometric and biochemical measurements

The diagnosis of hepatosteatosis was based on ultrasonography. Serum cholesterol, triglyceride, serum creatinine, and uric acid were obtained from the original datasets. Body mass index (BMI) was calculated as weight (in kilograms) divided by the square of the height (in meters). Mean arterial pressure (MAP) was calculated as MAP= (systolic pressure + 2 x diastolic pressure) /3.

Estimated glomerular filtration rate (eGFR) was calculated according to the 2009 CKD-EPI eGFR formula[12]: $eGFR = 141 \times min(SCr/\kappa, 1)^{\alpha} \times max(SCr/\kappa, 1)^{-1.209} \times 0.993^{Age} \times [1.018$ if female$] \times [1.159$ if Black$]$; $\kappa = 0.7$ (females) or 0.9 (males); $\alpha = -0.329$ (females) or -0.411 (males), where Scr is serum creatinine concentration (in mg/dL) and age refers to age in years.

CKD was defined as either decreased eGFR (<60ml/min/1.73^2) and/or abnormal albuminuria and/or overt proteinuria, in accordance with the Kidney Disease: Improving Global Outcome (KIDGO) 2012 Practice guideline for CKD[13].

CKD was classified into five stages based on the eGFR categories. Decline in GFR category represented CKD stage G1 to G5 (≥90 [G1], 60-89 [G2], 59-30 [G3], 15-29 [G4], <15 [G5] ml/min/ 1.73 m^2). The early stages of CKD were defined as CKD stage G1-G2, while the late stages of CKD were defined as stages 3-5.

Statistical analysis

Continuous variables were represented as mean ± standard deviation and compared using the Student's t-test. Categorical variables were expressed as counts (percentages) and compared using the Chi-squared test or the Fisher's exact test when the samples were limited in number. Binary logistic regressions including two models (Model 1 adjusted for age, sex, BMI. Model 1 adjusted for age, sex, BMI, history of diabetes and history of hypertension) were employed to find the relationship between renal function decline and the presence of NAFLD after correcting for different confounding factors of renal function. All tests were two-sided, and a p-value <0.05 were considered statistically significant. All analysis was conducted by SPSS version 23.0.

Results

Characteristics of participants

A total of 65085 participants were included in this study (Figure 1), with 11844 from the NHANES III dataset (the US population) and 51229 from the Chinese dataset (the Chinese population). The characteristics of all participants are shown in table 1. The difference in the age between two populations was statistically significant but less clinically significant (43.49±14.30 vs. 43.86±16.08, p=0.023). Compared with the US population, the Chinese population was more likely to be male (59.70% vs. 39.48%, p=0.019), had lower BMI levels (23.08±3.31 vs. 27.47±5.98, p<0.001) and lower proportions of diabetes (6.9% vs. 7.6%, p<0.001) or hypertension (21.8% vs. 25.5%, p<0.001).

The prevalence of NAFLD was 27.12% in the Chinese population and 36.08% in the US population (p<0.001). The NAFLD group had significantly higher age, BMI, blood glucose, blood pressure, cholesterol, and triglyceride level than the non-NAFLD group in both populations. The Chinese population had a higher eGFR level than the US population (91.48±17.06 vs. 80.15±18.65, p<0.001). Moreover, the proportion of CKD, especially the proportion of CKD stage 3-5, was lower in the Chinese participants than the US participants (for CKD: 9.1% vs.21.5%; for CKD stage 3-5: 4.0% vs.13.5%, both p<0.001).

Renal function and NAFLD in different populations

As shown in Table 2, CKD was prevalent in the NAFLD group than the non-NAFLD group in both populations (Chinese population: 12.3% vs. 8.0%, US population: 25.8% vs. 19.0%, both p<0.001). However, there were some differences in renal function between these two groups in different populations. The mean serum creatinine levels were not statistically different between NAFLD group and non-NAFLD group in the US population (93.35±25.88 vs. 93.62±30.90, p=0.636) while the eGFR were significantly lower in NAFLD group (78.45±18.78 vs. 81.10±18.51, p<0.001) in the US population. In Chinese population, both the serum creatinine and eGFR showed statistically different between two groups. As for the CKD with different stages, late stages CKD (stages 3-5) consisted of 2/3 of CKD patients in the US population while less than half of CKD patients were in stages 3-5 among Chinese population.

Associations between NAFLD and different stages of CKD

Table 3 shows the risk for CKD in NAFLD patients in different populations. In univariate logistic regression, NAFLD was significantly associated with CKD in both Chinese and US adults. In Chinese population, the NAFLD increased the risk of CKD but the strength of this affect attenuated with more confounding factors being adjusted: after adjusted for age, sex, BMI and histories of hypertension and diabetes, the OR dropped from 1.627 to 1.101. In the US population, the association between NAFLD and CKD was insignificant after adjustment for the same confounding factors (P>0.05).

To explore the possible explanation for this discrepancy between two countries, we performed a subgroup analysis by stratifying cases by the severity of CKD. As shown in Table 2, the US population had higher proportion of late stages CKD (CKD stages 3-5), so firstly, we evaluated the risk for late stages of CKD. The results showed that NAFLD was not significantly associated with late stage CKD in both Chinese population and the US population after adjustment for same metabolic factors (all P>0.05). Then we excluded those with late stages CKD and calculated the risk of early stages of CKD in NAFLD patients. As shown in table 3, NAFLD was an independent risk for early renal function decline in both populations after adjustment (OR 1.346-1.513 in Chinese population and 1.160-1.284 in US population, all P<0.05).

Discussion

NAFLD and CKD share similar pathological mechanisms; therefore they are speculated to have some links. This cross-sectional study analyzed the association between ultrasound-defined NAFLD and CKD in two health examination datasets from the US and China. The results of this study confirmed the higher prevalence of CKD among patients with NAFLD. Slightly difference was found between Chinese and US population in this study: in the Chinese population, NAFLD was significantly associated with increased risk of CKD after adjustment for metabolic factors, but in the US population, no significant association was found after adjustment for the same factors. However, when we excluded patients with advanced reduced renal function (eGFR<60 ml/min/ 1.73 m^2, CKD stages 3-5), NAFLD was significantly connected with increased risk for early renal function decline in both populations.

The discrepancy between eastern and western population regarding the relationship between NAFLD and CKD has already been found by previous studies. Sirota et al.[9] found that NAFLD is not associated with the prevalence of CKD among US adults after adjusting for features of metabolic syndrome. While other studies from Asia reported a strong independent risk of CKD in ultrasonography-diagnosed NAFLD patients [10, 14, 15]. The meta-analysis also confirm the difference between Asian and European populations[6]. The reason for this discrepancy has not been clarified since all the studies were not analyzed under same statistical condition. In present study, in order to compare the association of NAFLD and CKD in different populations, we creatively calculated the risks for CKD by adjustment for same confounders in different datasets. Consistent with previous studies, we confirmed the ethnic difference in the relationship between CKD and NAFLD in two population-based datasets.

The answer for the ethnic difference on the relationship between NAFLD and CKD might result from different proportion of severe renal dysfunction. The US population had a higher percentage of stages 3-5 CKD than the Chinese population. In fact, after we excluded those with late stages of CKD, NAFLD was strongly associated with early renal decline in both populations. Supporting our results, several prospective studies confirmed the influence of NALFD on the development of CKD, most of which were developed from the early stages[16-18]. But an important fact we should emphasize is that, compared with the early stage of CKD, the later stage of CKD is more complicated and severe. For example, increased synthesis and decreased clearance of triglycerides, extremely altered glucose homeostasis and uncontrollable blood pressure are more common among patients with late stages CKD[19-21]. Thus NAFLD might have an impact on renal function, yet it alone apparently not strong enough to contribute to the late stage function decline when severe renal decline is concerned. That explains why the association between late stages of CKD and NAFLD is not significant in both populations. When there are more late stages of CKD, such as the US population, the relationship of NALFD and CKD might attenuate during multivariate analysis.

To our best knowledge, this study is the first to compare the association between NAFLD and early renal function decline across different ethnicities. And we also answer the questions of conflicting conclusion from different countries from some aspects. The results of our study suggest that NAFLD plays a more important role in mild renal dysfunction, which providing more evidences for the hypothesis that pre-existing NAFLD is an independent risk factor for the development of renal injury. Yet there are several limitations in this study that deserve a mention. Given the cross-sectional design of this study, we are unable to draw conclusions about the causality of the relationship between NAFLD and early renal function decline. Secondly, we have not use cystatin C to define eGFR, which is less affected than creatinine by muscle mass and more accurate for different ethnicities.

In conclusion, our findings demonstrated a significant positive association between the presence of NAFLD and early stage of CKD in both US and Chinese adults. For the late stages of CKD, NAFLD might not be strong enough to be an independent contributor.

Declarations

Ethics approval and consent to participate⬚The studies were approved by the institutional review board at each participating center. Written informed consent was obtained from all subjects in the original studies. All methods were performed in accordance with the Declaration of Helsinki regarding ethical standards for research involving human subjects.

Consent for publication⬚Not applicable.

Competing interests: The authors declare that they have no competing interests.

Fundings: This project was funded by the Fujian provincial health technology project(2018-ZQN-54), the Chinese National 13th Five-Year Plan's Science and Technology Projects(2017ZX10202201) and Qingzhong Medical Science Research Fund(B17344).

Author Contributions: Guarantor of the article: Xiaozhong Wang; Designed the study, interpreted data and wrote the manuscript: Su Lin and Min Zhang; Screened and extracted data: Shiying Liu, Sumei Wu ,Wenyue Liu and Dongchu Zhang; Statistical analyses: Jiaofeng Huang, Mingfang Wang, Haoyang Zhang and Zimu Wu; Reviewed the results and made critical comments on the manuscript: Minghua Zheng, Yueyong Zhu, Chuanming Hao, and Xiaozhong Wang; All authors approved the final version of the manuscript.

Acknowledgments: Not applicable.

References

1. Araujo, A.R., et al., *Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future.* Liver Int., 2018. **38 Suppl 1**: p. 47-51.

2. Han, E. and Y.H. Lee, *Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases.* Diabetes Metab J, 2017. **41**(6): p. 430-437.

3. Sookoian, S. and C.J. Pirola, *Review article: shared disease mechanisms between non-alcoholic fatty liver disease and metabolic syndrome – translating knowledge from systems biology to the bedside.* Alimentary Pharmacology & Therapeutics, 2019. **49**(5): p. 516-527.

4. Targher, G., M.B. Chonchol, and C.D. Byrne, *CKD and nonalcoholic fatty liver disease.* Am J Kidney Dis, 2014. **64**(4): p. 638-52.

5. Targher, G., et al., *Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis.* Clin J Am Soc Nephrol, 2010. **5**(12): p. 2166-71.

6. Mantovani, A., et al., *Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis.* Metabolism, 2018. **79**: p. 64-76.

7. Singal, A.K., et al., *Evolving frequency and outcomes of liver transplantation based on etiology of liver disease.* Transplantation, 2013. **95**(5): p. 755-60.

8. Houlihan, D.D., et al., *Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens?* Liver Transpl, 2011. **17**(11): p. 1292-8.

9. Sirota, J.C., et al., *Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994.* Am J Nephrol, 2012. **36**(5): p. 466-71.

10. Yun, K.E., et al., *Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans.* Atherosclerosis, 2009. **205**(2): p. 533-7.

11. Sun, D.-Q., et al., *Association of low-density lipoprotein cholesterol within the normal range and NAFLD in the non-obese Chinese population: a cross-sectional and longitudinal study.* BMJ Open, 2016. **6**(12): p. e013781.

12. Levey, A.S., et al., *A new equation to estimate glomerular filtration rate.* Ann Intern Med, 2009. **150**(9): p. 604-12.

13. Inker, L.A., et al., *KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.* Am J Kidney Dis, 2014. **63**(5): p. 713-35.

14. Li, G., et al., *Nonalcoholic fatty liver disease associated with impairment of kidney function in nondiabetes population.* Biochem Med (Zagreb), 2012. **22**(1): p. 92-9.

15. Wang, L., *Ultrasound-Diagnosed Nonalcoholic Fatty Liver Disease Independently Predicts a Higher Risk of Developing Diabetes Mellitus in Nonoverweight Individuals.* Acad Radiol, 2018.

16. Arase, Y., et al., *The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease.* Intern Med, 2011. **50**(10): p. 1081-7.

17. Chang, Y., et al., *Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men.* Metabolism, 2008. **57**(4): p. 569-76.

18. Targher, G., et al., *Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease.* J Am Soc Nephrol, 2008. **19**(8): p. 1564-70.

19. Chmielewski, M., et al., *Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach.* J Nephrol, 2008. **21**(5): p. 635-644.

20. Moradi, H. and N.D. Vaziri, *Molecular mechanisms of disorders of lipid metabolism in chronic kidney disease.* 2018.

21. Plantinga, L.C., et al., *Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999–2006.* Hypertension, 2009. **54**(1): p. 47-56.

Tables

Table 1: Characteristics and comparison of US data and Chinese data

	US data (n=11844)				Chinese data (n=51229)				P value (NHANES vs Chinese)
	Total (n=11844)	non-NAFLD Group (n=7571)	NAFLD Group (n=4273)	P value	Total (n=51229)	non-NAFLD Group (n=37334)	NAFLD Group (n=13895)	P value	
Male gender, n(%)	5325(45.0%)	3332(44.0%)	1993(46.6%)	0.006	30582(59.7%)	19179(51.4%)	11403(82.1%)	<0.001	<0.001
Age (years)	43.86±16.08	42.18±16.03	46.82±15.75	<0.001	43.49±14.30	42.12±14.48	47.18±13.12	<0.001	0.023
BMI (Kg/m^2)	27.38±5.90	26.16±5.02	29.56±6.67	<0.001	23.08±3.31	22.07±2.87	25.82±2.82	<0.001	<0.001
Diabetes, n(%)	896(7.6%)	354(4.7%)	542(12.7%)	<0.001	3544(6.9%)	1540(4.1%)	2004(14.4%)	<0.001	<0.001
Hypertension, n(%)	2935(25.0%)	1600(21.3%)	1335(31.5%)	<0.001	11176(21.8%)	5821(15.6%)	5355(38.5%)	<0.001	<0.001
Blood glucose (mmol/l)	5.62±2.09	5.35±1.52	6.11±2.77	<0.001	5.36±1.04	5.22±0.83	5.74±1.38	<0.001	<0.001
Mean arterial pressure (mmHg)	91.50±28.34	89.97±27.65	97.17±30.10	<0.001	92.03±12.39	89.58±11.84	98.61±11.43	<0.001	0.002
Diastolic pressure (mmHg)	75.29±28.92	74.43±31.34	76.83±29.96	<0.001	76.61±11.33	74.39±10.73	82.56±10.75	<0.001	<0.001
Systolic pressure (mmHg)	123.91±30.45	122.03±31.75	1276.26±27.67	<0.001	122.88±16.62	119.96±16.06	130.71±15.55	<0.001	<0.001
Serum cholesterol (mmol/l)	5.29±1.18	5.21±1.15	5.42±1.22	<0.001	4.71±0.94	4.58±0.90	5.04±0.98	<0.001	<0.001
Serum triglyceride (mmol/l)	1.65±1.28	1.56±1.21	2.00±1.46	<0.001	1.57±1.42	1.26±1.02	2.39±1.92	<0.001	<0.001
Uric acid (umol/l)	313.86±87.36	306.04±82.63	342.51±97.66	<0.001	307.37±92.74	287.9±86.75	359.69±87.96	<0.001	<0.001
NFS	-2.09±1.63	-2.36±1.50	-1.10±1.71	<0.001	-1.76±1.24	-1.83±1.22	-1.55±1.25	<0.001	<0.001
FIB4	0.93±0.65	0.82±0.56	1.30±0.81	<0.001	1.32±0.85	1.31±0.88	1.33±0.75	0.010	<0.001
APRI	0.21±0.19	0.21±0.19	0.22±0.20	0.002	0.34±0.26	0.31±0.26	0.38±0.24	<0.001	<0.001

Table 2 Comparison of the renal function index between US data and Chinese data

	US data (n=11844)				Chinese data (n=51229)				P value
	Total (n=11844)	non-NAFLD Group (n=7571)	NAFLD Group (n=4273)	P value	Total (n=51229)	non-NAFLD Group (n=37334)	NAFLD Group (n=13895)	P value	(NHANES vs Chinese)
Serum creatinine (umol/l)	93.52±29.19	93.62±30.90	93.35±25.88	0.636	82.92±20.82	80.92±21.70	88.29±17.14	<0.001	<0.001
eGFR (ml/min/1.73^2)	80.15±18.65	81.10±18.51	78.45±18.78	<0.001	91.48±17.06	93.03±17.31	87.32±15.62	<0.001	<0.001
Proteinuria, n(%)	1305(11.0%)	714(9.4%)	591(13.8%)	<0.001	3231(6.3%)	1977(5.3%)	1254(9.0%)	<0.001	<0.001
CKD, n(%)	2544(21.5%)	1441(19.0%)	1103(25.8%)	<0.001	4685(9.1%)	2971(8.0%)	1714(12.3%)	<0.001	<0.001
CKD Categories, n(%)									
G0, n(%)	9300(78.5%)	6130(81.0%)	3170(74.2%)		46544(90.9%)	34363(92.0%)	12181(87.7%)	<0.001	<0.001
G1-2, n(%)	958(8.1%)	521(6.9%)	434(10.2%)		2659(5.2%)	1616(4.4%)	1043(7.5%)	<0.001	<0.001
G3-5 , n(%)	1586(13.5%)	917(12.1%)	669(15.7%)		2026(4.0%)	1355(3.6%)	671(4.8%)	<0.001	<0.001

Table 3: Binary logistic regression analysis of NAFLD and CKD

Risk for CKD		US data			Chinese data		
		OR of NAFLD	95% CI	P value	OR of NAFLD	95% CI	P value
All stages of CKD	Unadjusted	1.480	1.354-1.619	<0.001	1.627	1.528-1.733	<0.001
	Model1	1.071	0.964-1.191	0.203	1.181	1.094-1.274	<0.001
	Model 2	0.993	0.891-1.107	0.902	1.101	1.019-1.189	0.015
CKD stages3-5	Unadjusted	1.347	1.210-1.500	<0.001	1.347	1.226-1.481	<0.001
	Model1	0.921	0.804-1.055	0.235	1.034	0.913-1.171	0.594
	Model 2	0.904	0.788-1.038	0.152	1.025	0.904-1.162	0.698
CKD stages 1-2	Unadjusted	1.520	1.331-1.737	<0.001	1.794	1.655-1.944	<0.001
	Model1	1.284	1.116-1.479	0.001	1.513	1.374-1.666	<0.001
	Model 2	1.160	1.003-1.340	0.045	1.346	1.220-1.485	<0.001

Model 1 Adjusted for age, sex, BMI. Model 2 Adjusted for age, sex, BMI, history of diabetes, history of hypertension.

Figures

Figure 1

Flow-chart of cases screening.